微信公众号
News Center
Knowledge Lecture Hall
2024-06-22
GP2 (Glycoprotein 2) is widely distributed among species, present in mammals, poultry, and even some fish; this wide distribution indicates the importance of GP2's conservation across different animal species.
Learn More Details
2024-06-14
High-grade serous carcinoma (HGSC) is a malignant tumor and the most common and aggressive histological type of ovarian cancer. It typically presents with rapidly dividing and highly atypical cells, characterized by significant nuclear atypia and prominent nucleoli.
Learn More Details
2024-06-14
BRAF Gene Mutation and Selection of Testing Schemes
Rat sarcoma (RAS)/Rapidly Accelerated Fibrosarcoma (RAF)/Mitogen-Activated Protein Kinase Kinase (MEK)/Extracellular Signal-Regulated Kinase (ERK) or Mitogen-Activated Protein Kinase (MAPK) signaling pathway is a key intracellular signaling pathway that mediates growth signal responses essential for cell proliferation and survival.
Learn More Details
2024-05-27
Modern Pathology丨PITX2 as a Sensitive and Specific Marker for Midgut Neuroendocrine Tumors
Neuroendocrine tumors (NETs) often present as metastatic lesions, and immunohistochemical localization of the site of origin is one of the most important tasks in their pathological assessment.
Learn More Details
2024-04-26
AM J SURG PATHOL | GAD2 is a highly specific marker for pancreatic neuroendocrine tumors
Glutamate decarboxylase 2 (GAD2, also known as GAD65) is one of the two glutamate decarboxylases required for converting glutamate to γ-aminobutyric acid (GABA). GABA is the most important inhibitory neurotransmitter in the central nervous system, capable of reducing the excitability of neurons at nerve terminals and synapses.
Learn More Details
2024-04-26
Latest Advances and Diagnostic Challenges in Endometrial Cancer (Part 2)
The depth of myometrial invasion is an independent predictor of lymph node involvement and overall survival in patients with endometrial carcinoma. Staging requires reporting the absence or presence of myometrial invasion (pT1a, none or <50% myometrial invasion; pT1b, ≥50% myometrial invasion).
Learn More Details